SpliSense is a clinical stage company developing transformative RNA-based treatments for unmet needs relating to diverse pulmonary diseases. Its treatment is based on clinically validated Antisense Oligonucleotide (ASO) technology, delivered non-invasively by inhalation to the lungs. The company is focused on a variety of innovative therapies, in different development stages from discovery to IND. Using an innovative approach, SpliSense aims to target the root cause of the disease, to overcome specific genetic mutations and modulate proteins expression and function. The company recieved FDA approval for its lead ASO product, SPL84, for the treatment of patients with cystic fibrosis.